- In October 2024, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract disease (LRTD) caused by RSV in individuals aged 18 to 59 who are at higher risk for RSV-related LRTD. ABRYSVO now provides the broadest RSV vaccine indication for adults, expanding beyond the previous approval for those aged 60 and older
- In October 2024, Merck announced the presentation of positive results from the Phase 2b/3 clinical trial (MK-1654-004), which assessed clesrovimab, the company’s investigational prophylactic monoclonal antibody, designed to protect infants from respiratory syncytial virus (RSV) during their first RSV season
- In June 2024, GSK plc announced that the U.S. Food and Drug Administration (FDA) had approved Arexvy (Respiratory Syncytial Virus (RSV) Vaccine, Adjuvanted) for preventing RSV-related lower respiratory tract disease (LRTD) in adults aged 50 to 59 who are at increased risk
- In May 2024, Moderna, Inc. announced that the U.S. Food and Drug Administration (FDA) had approved mRESVIA (mRNA-1345), an mRNA-based respiratory syncytial virus (RSV) vaccine, to protect adults aged 60 and older from lower respiratory tract disease caused by RSV infection. This approval, granted under breakthrough therapy designation, marks the second mRNA product from Moderna to receive approval
- In May 2023, GSK plc announced that the U.S. Food and Drug Administration (FDA) had approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for preventing lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals aged 60 and older. This marks the first approval of an RSV vaccine for older adults worldwide
Frequently Asked Questions
Companies such as GSK plc. (UK), Pfizer Inc. (U.S.), Moderna, Inc. (U.S.), Merck & Co., Inc. (U.S.) and AstraZeneca (UK) are the major companies in the respiratory syncytial virus vaccines market.
In October 2024, Pfizer Inc. announced that the U.S. Food and Drug Administration (FDA) had approved ABRYSVO (Respiratory Syncytial Virus Vaccine), a bivalent RSV prefusion F (RSVpreF) vaccine, for preventing lower respiratory tract disease (LRTD) caused by RSV in individuals aged 18 to 59. In May 2023, GSK plc announced that the U.S. Food and Drug Administration (FDA) had approved Arexvy (respiratory syncytial virus vaccine, adjuvanted) for preventing lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals aged 60 and older.
The countries covered in the respiratory syncytial virus vaccines market are U.S., Canada and Mexico, Germany, France, U.K., Italy, Russia, Spain, Denmark, Sweden, Norway, Rest of Europe, China, Japan, India, South Korea, Australia, Thailand, Rest of Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Nigeria, Egypt, Kuwait, Rest of Middle East and Africa, Brazil, Argentina and Rest of South America.
